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Background: In the HORIZONS AMI trial, bivalirudin monotherapy (Biv) compared to unfractionated heparin (UFH) plus gp IIb/IIIa inhibitors 
(GPI) resulted in reduced rates of major bleeding, decreased cardiac mortality and net adverse clinical events (NACE) in pts with STEMI undergoing 
primary PCI at 1 year. Whether the beneficial effects of Biv are independent of diabetic status and are sustained long term has not been reported.
Methods: and Results: A total of 3602 pts with AMI undergoing primary PCI were randomized 1:1 to Biv vs. UFH+GPI and followed for 3 years. 
Outcomes were analyzed according to the presence of diabetes mellitus (DM) at the time of admission. Compared to pts without DM, those with 
DM (n=593; 16.4%) had greater rates of major bleeding (11.5% vs. 8.2%, P=0.01), MACE (29.6% vs. 20.3%, P<0.0001), NACE (34.5% vs. 25.0%, 
P<0.0001) and mortality (11.4% vs. 5.9%, p<0.0001) at 3 years. In the entire study population, Biv compared to UFH+GPI resulted in a 36% 
reduction in major bleeding (6.9% vs. 10.5%, P<0.0001), a 24% reduction in reinfarction (6.2% vs. 8.2%, P=0.04), and a 44% reduction in cardiac 
mortality (5.1% vs. 2.9%, P=0.001). Clinical outcomes in the DM and non-DM subgroups at 3 years are shown in the Table. The impact of Biv was 
independent of DM.
Conclusions: In pts with AMI undergoing primary PCI, initial treatment with Biv resulted in sustained reductions in major bleeding, reinfarction and 
cardiac death at 3 years. The absolute survival benefit of Biv is particularly pronounced in the DM pts. 
Diabetes (n=593) No diabetes (n=3006)
Biv mono UFH+GPI
RR
[95%CI]
Biv mono UFH+GPI
RR
[95%CI]
Major bleeding 9.9% 12.9% 0.76 [0.47,1.25] 6.4% 10.0% 0.61 [0.47,0.80]
Death/
Reinfarction
15.2% 21.2% 0.69 [0.47,1.03] 10.6% 13.1% 0.80 [0.65,0.99]
Cardiac Death 4.5% 9.9% 0.44 [0.22,0.86] 2.6% 4.0% 0.64 [0.42,0.96]
